Skip to main content

Advertisement

Table 1 Prognostic value of MYPT1 expression for the biochemical recurrence-free, metastasis-free and overall survival in univariate and multivariate analysis using Cox Regression models

From: MicroRNA-30d promotes angiogenesis and tumor growth via MYPT1/c-JUN/VEGFA pathway and predicts aggressive outcome in prostate cancer

  Univariate Multivariate
  HR 95% Cl P HR 95% Cl P
Time to BCR       
 MYPT1 (high vs low) 0.371 0.232–0.593 <0.001 0.468 0.282–0.775 0.003
 Tumor stage (T2 vs T3) 1.879 1.207–2.925 0.005 1.123 0.668–1.888 0.661
 Surgical margin (+ vs -) 1.805 1.185–2.749 0.006 1.124 0.673–1.876 0.655
 Gleason score (<8 vs ≥8) 4.541 2.832–7.280 <0.001 3.482 2.010–6.033 <0.001
 Pre-operative PSA (<4 vs ≥4) 1.792 1.090–2.947 0.022 1.941 0.877–4.300 0.102
 Age (<66 vs ≥66) 1.502 0.973–2.320 0.067 1.361 0.848–2.183 0.201
 Time to Metastasis       
 MYPT1 (high vs low) 0.376 0.137–1.035 0.058 0.420 0.148–1.191 0.103
 Tumor stage (T2 vs T3) 1.574 0.628–3.946 0.333 1.179 0.401–3.464 0.764
 Surgical margin (+ vs -) 0.963 0.394–2.356 0.934 0.608 0.208–1.781 0.364
 Gleason score (<8 vs ≥8) 4.765 1.945–11.672 0.001 3.563 1.258–10.094 0.017
 Pre-operative PSA (<4 vs ≥4) 1.780 0.676–4.684 0.243 0.577 0.202–1.649 0.305
 Age (<66 vs ≥66) 0.940 0.361–2.448 0.900 0.744 0.265–2.091 0.575
Time to Death       
 MYPT1 (high vs low) 0.375 0.183–0.768 0.007 0.334 0.150–0.742 0.007
 Tumor stage (T2 vs T3) 1.626 0.852–3.103 0.140 1.305 0.604–2.823 0.498
 Surgical margin (+ vs -) 1.178 0.636–2.183 0.603 0.534 0.250–1.142 0.106
 Gleason score (<8 vs ≥8) 4.033 2.111–7.705 <0.001 2.941 1.335–6.477 0.007
 Pre-operative PSA (<4 vs ≥4) 1.275 0.600–2.713 0.527 1.045 0.388–2.814 0.931
 Age (<66 vs ≥66) 1.818 0.980–3.369 0.058 1.876 0.952–3.695 0.069
  1. HR Hazard ratio, CI confidence interval; Surgical margin status, between positive and negative